Kati Maharry

3.9k total citations · 1 hit paper
33 papers, 1.1k citations indexed

About

Kati Maharry is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Kati Maharry has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 13 papers in Hematology. Recurrent topics in Kati Maharry's work include Colorectal Cancer Treatments and Studies (15 papers), Acute Myeloid Leukemia Research (13 papers) and Lung Cancer Treatments and Mutations (12 papers). Kati Maharry is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Acute Myeloid Leukemia Research (13 papers) and Lung Cancer Treatments and Mutations (12 papers). Kati Maharry collaborates with scholars based in United States, Australia and Spain. Kati Maharry's co-authors include Rona Yaeger, Ashwin Gollerkeri, Harpreet Wasan, Jayesh Desai, Scott Kopetz, Fortunato Ciardiello, Josep Tabernero, Janna Christy‐Bittel, Takayuki Yoshino and Eric Van Cutsem and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Kati Maharry

32 papers receiving 1.1k citations

Hit Papers

Encorafenib Plus Cetuximab as a New Standard of Care for ... 2021 2026 2022 2024 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
    2021 331 citations Josep Tabernero, Axel Grothey et al. Journal of Clinical Oncology profile →

Peers

Kati Maharry
Comparison fields: 5 of 63
  • Oncology 673
  • Molecular Biology 512
  • Pathology and Forensic Medicine 280
  • Hematology 271
  • Pulmonary and Respiratory Medicine 211
Replace Joanne Lager with:
Joanne Lager United States
H. J. Illiger Germany
Daphne Voorn Netherlands
Miyuki Akutsu Japan
Jean Powers Canada
E.L. Kwak United States
Chetasi Talati United States
Masafumi Takimoto Japan
Olaf Christensen United States
Valérie Méresse France
Joanne Lager United States View profile →
Citations per field, relative to Kati Maharry
Kati Maharry · 1×
Citations per year, relative to Kati Maharry
Kati Maharry · 1×

Countries citing papers authored by Kati Maharry

Since Specialization
Citations

This map shows the geographic impact of Kati Maharry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kati Maharry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kati Maharry more than expected).

Fields of papers citing papers by Kati Maharry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kati Maharry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kati Maharry. The network helps show where Kati Maharry may publish in the future.

Co-authorship network of co-authors of Kati Maharry

This figure shows the co-authorship network connecting the top 25 collaborators of Kati Maharry. A scholar is included among the top collaborators of Kati Maharry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kati Maharry. Kati Maharry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study breakdown →
2021 ·Journal of Clinical Oncology ·Josep Tabernero, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik-Tobias Arkenau, Pilar García‐Alfonso, Élena Elez, Ashwin Gollerkeri, Kati Maharry, Janna Christy‐Bittel, Scott Kopetz
331
2
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
2021 ·ESMO Open ·Josep Tabernero, (unknown), (unknown), Axel Grothey, Rona Yaeger, Eric Van Cutsem, Harpreet Wasan, Jayesh Desai, Fortunato Ciardiello, Takayuki Yoshino, Ashwin Gollerkeri, Kati Maharry, Janna Christy‐Bittel, Scott Kopetz
15
3
85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)
2020 ·Annals of Oncology ·(unknown), (unknown), Kun‐Huei Yeh, Jayesh Desai, Timothy Price, (unknown), Josep Tabernero, (unknown), (unknown), Axel Grothey, Rona Yaeger, Ashwin Gollerkeri, Kati Maharry, Scott Kopetz
1
4
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
2020 ·Journal of Clinical Oncology ·Scott Kopetz, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Ashwin Gollerkeri, Kati Maharry, Janna Christy‐Bittel, Josep Tabernero
32
5
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
2020 ·Journal of Clinical Oncology ·Scott Kopetz, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Ashwin Gollerkeri, Kati Maharry, Janna Christy‐Bittel, Christopher Hunt Keir, Michael D. Pickard, Josep Tabernero
19
6
LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC
2020 ·Annals of Oncology ·Axel Grothey, Scott Kopetz, Rona Yaeger, Eric Van Cutsem, Harpreet Wasan, Jayesh Desai, Fortunato Ciardiello, Takayuki Yoshino, Kati Maharry, Janna Christy‐Bittel, Ashwin Gollerkeri, Josep Tabernero
1
7
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
2020 ·Journal of Clinical Oncology ·Scott Kopetz, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Ashwin Gollerkeri, Kati Maharry, Janna Christy‐Bittel, Christopher Hunt Keir, Michael D. Pickard, Josep Tabernero
17
8
BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer
2019 ·Annals of Oncology ·Scott Kopetz, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Ashwin Gollerkeri, Kati Maharry, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar Alfonso, V. Sandor, Janna Christy‐Bittel, Lisa Anderson, Josep Tabernero
14
9
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
2019 ·Journal of Clinical Oncology ·Eric Van Cutsem, Sanne C.F.A. Huijberts, Axel Grothey, Rona Yaeger, (unknown), Élena Elez, Marwan Fakih, Clara Montagut, Marc Peeters, Takayuki Yoshino, Harpreet Wasan, Jayesh Desai, Fortunato Ciardiello, Ashwin Gollerkeri, Janna Christy‐Bittel, Kati Maharry, Victor Sandor, Jan H.M. Schellens, Scott Kopetz, Josep Tabernero
152
10
BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.
2018 ·Journal of Clinical Oncology ·Eric Van Cutsem, Pieter‐Jan Cuyle, Sanne C.F.A. Huijberts, Rona Yaeger, Jan H.M. Schellens, Élena Elez, Josep Tabernero, Marwan Fakih, Clara Montagut, Marc Peeters, Jayesh Desai, Takayuki Yoshino, Fortunato Ciardiello, Harpreet Wasan, Scott Kopetz, Kati Maharry, Janna Christy‐Bittel, Ashwin Gollerkeri, Axel Grothey
32
11
BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)
2017 ·Annals of Oncology ·Sanne C.F.A. Huijberts, Jan H.M. Schellens, Élena Elez, (unknown), Eric Van Cutsem, Rona Yaeger, Marwan Fakih, Clara Montagut, Marc Peeters, Jayesh Desai, Takayuki Yoshino, Fortunato Ciardiello, Harpreet Wasan, Axel Grothey, Kati Maharry, Ashwin Gollerkeri, Scott Kopetz
3
12
Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808
2013 ·Cancer ·Jonathan E. Kolitz, Stephen L. George, Don M. Benson, Kati Maharry, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Courtney E. Bakan, Vera Hárs, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Richard A. Larson
20
13
SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)
2012 ·Blood ·Houda Alachkar, Kati Maharry, Ramasamy Santhanam, Paolo Neviani, Stefano Volinia, Jessica Kohlschmidt, Klaus H. Metzeler, Adrienne M. Dorrance, Sebastian Schwind, Heiko Becker, Jason H. Mendler, Ann‐Kathrin Eisfeld, Susan P. Whitman, Krzysztof Mrózek, Ramiro Garzon, Danilo Perrotti, Michael A. Caligiuri, Richard M. Stone, Guido Marcucci, Clara D. Bloomfield
0
14
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.
2009 ·Blood ·Heiko Becker, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Susan P. Whitman, Peter Paschka, Dean Margeson, Yue-Zhong Wu, Sebastian Schwind, Christian Langer, Maria R. Baer, Andrew J. Carroll, Michael A. Caligiuri, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield
19
15
Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.
2009 ·Blood ·Susan P. Whitman, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Heiko Becker, (unknown), Sebastian Schwind, Maria R. Baer, Bayard L. Powell, Richard M. Stone, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield
4
16
NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML)
2009 ·Journal of Clinical Oncology ·Heiko Becker, Guido Marcucci, Kati Maharry, Dean Margeson, Michael D. Radmacher, Susan P. Whitman, Krzysztof Mrózek, Maria R. Baer, Richard A. Larson, Clara D. Bloomfield
3
17
Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study.
2009 ·Blood ·Krzysztof Mrózek, Kelsi B. Holland, Mark J. Pettenati, Kati Maharry, Guido Marcucci, Maria R. Baer, Jonathan E. Kolitz, Dean Margeson, Colin G. Edwards, Andrew J. Carroll, Richard A. Larson, Clara D. Bloomfield
2
18
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication
2008 ·Blood ·Susan P. Whitman, Björn Hackanson, Sandya Liyanarachchi, Shujun Liu, Laura J. Rush, Kati Maharry, Dean Margeson, Ramana V. Davuluri, Jing Wen, (unknown), Li Yu, Chunhui Liu, Clara D. Bloomfield, Guido Marcucci, Christoph Plass, Michael A. Caligiuri
56
19
Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study.
2007 ·Blood ·Peter Paschka, Guido Marcucci, Amy S. Ruppert, Krzysztof Mrózek, Susan P. Whitman, Kati Maharry, Christian Langer, Claudia D. Baldus, Bayard L. Powell, Maria R. Baer, Andrew J. Carroll, Michael A. Caligiuri, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield
3
20
Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity
2005 ·Journal of Clinical Oncology ·Guido Marcucci, Wendy Stock, Guowei Dai, Rebecca B. Klisovic, Shujun Liu, Marko I. Klisovic, William Blum, Cheryl Kefauver, Dorie A. Sher, Margaret Green, Mollie E. Moran, Kati Maharry, Steven Novick, Clara D. Bloomfield, James A. Zwiebel, Richard A. Larson, Michael R. Grever, Kenneth K. Chan, John C. Byrd
112

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joanne Lager Breakdown of academic impact, for papers by H. J. Illiger Breakdown of academic impact, for papers by Daphne Voorn Breakdown of academic impact, for papers by Miyuki Akutsu Breakdown of academic impact, for papers by Jean Powers Breakdown of academic impact, for papers by E.L. Kwak Breakdown of academic impact, for papers by Chetasi Talati Breakdown of academic impact, for papers by Masafumi Takimoto Breakdown of academic impact, for papers by Olaf Christensen Breakdown of academic impact, for papers by Valérie Méresse
Rankless by CCL
2026